Last reviewed · How we verify
Bactek-R
Bactek-R is a bacterial lysate immunotherapy that stimulates innate and adaptive immune responses to enhance respiratory tract defenses.
Bactek-R is a bacterial lysate immunotherapy that stimulates innate and adaptive immune responses to enhance respiratory tract defenses. Used for Recurrent respiratory tract infections.
At a glance
| Generic name | Bactek-R |
|---|---|
| Sponsor | Inmunotek S.L. |
| Drug class | Bacterial lysate immunotherapy |
| Modality | Biologic |
| Therapeutic area | Immunology / Respiratory |
| Phase | Phase 3 |
Mechanism of action
Bactek-R contains inactivated bacterial components designed to activate pattern recognition receptors and promote mucosal and systemic immunity. This mechanism aims to reduce the frequency and severity of respiratory tract infections by priming the immune system against common respiratory pathogens.
Approved indications
- Recurrent respiratory tract infections
Common side effects
- Local injection site reactions
- Mild fever
- Gastrointestinal symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bactek-R CI brief — competitive landscape report
- Bactek-R updates RSS · CI watch RSS
- Inmunotek S.L. portfolio CI